Safety and efficacy profile of Spiriva® Respimat® in the treatment of COPD
TIOSPIR™ (Tiotropium Safety and Performance in Respimat), with over 17,000 COPD patients included, was one of the largest international COPD trials ever conducted, confirmed the comparable mortality and exacerbation efficacy profile of Spiriva® Respimat® 5mcg and Spiriva® HandiHaler® 18mug.(1)
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: ebercott Tags: *** Editor's Pick Respiratory Latest News Source Type: news
More News: Chronic Obstructive Pulmonary | Drugs & Pharmacology | Respiratory Medicine | Spiriva | Tiotropium